Gami­da Cell looks to get $22M+ on its pub­lic of­fer­ing launch; Es­pe­ri­on signs co-pro­mo­tion pact with Cur­rax

The cell ther­a­py biotech Gami­da Cell went for­ward with its pub­lic of­fer­ing on the back of FDA ap­proval for Omisirge (omidu­bi­cel-on­lv), its al­lo­gene­ic cord blood-based cell ther­a­py used to quick­en the re­cov­ery of white blood cells for can­cer pa­tients.

On Wednes­day, Gami­da Cell an­nounced that it is sell­ing 17.5 mil­lion shares in its pub­lic of­fer­ing, and it ex­pects to bring in around $22.8 mil­lion in to­tal be­fore ex­pens­es. The of­fer is ex­pect­ed to close on Apr. 21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.